The emerging era of pharmacogenomics: Current successes, future potential, and challenges

Clinical Genetics

Volumn 86, Issue 1, 2014, Pages 21-28

  Lee, J W ^a,b   Aminkeng, F ^a,b   Bhavsar, A P ^a,b   Shaw, K ^b,c   Carleton, B C ^a,b,c   Hayden, M R ^a   Ross, C J D ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

Author keywords

ADRs; Adverse drug reactions; Anthracycline; Carbamazepine; Cisplatin; Codeine; Pharmacogenomics; Warfarin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBAMAZEPINE; CISPLATIN; CODEINE; WARFARIN; ANTHRACYCLINE; PHARMACOLOGICAL BIOMARKER;

CLINICAL PRACTICE; DRUG RESPONSE; DRUG SAFETY; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; GENETIC SCREENING; GENETIC VARIATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; TRENDS;

ANTHRACYCLINES; BIOMARKERS, PHARMACOLOGICAL; CARBAMAZEPINE; CISPLATIN; CODEINE; GENETIC TESTING; GENETIC VARIATION; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; WARFARIN;

EID: 84901440756     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12392     Document Type: Review

References (79)

1. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998: 8 (4): 283-289.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998: 279 (15): 1200-1205.
3. Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacol Res 2004: 49 (4): 363-373.
4. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013: 4: S73-S77.
5. Volpe D, McMahon Tobin G, Mellon R et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011: 59 (3): 385-390.
6. Madadi P, Ross CJ, Hayden MR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009: 85 (1): 31-35.
7. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006: 368 (9536): 704.
8. Ciszkowski C, Madadi P, Phillips M, Lauwers A, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009: 361 (8): 827-828.
9. Kelly L, Rieder M, van den Anker J et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012: 129 (5): 7.
10. Madadi P, Amstutz U, Rieder M et al. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol 2013: 20 (3): 96.
11. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004: 351 (27): 2827-2831.
12. Somogyi A, Barratt D, Coller J. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007: 81 (3): 429-444.
13. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009: 19 (2): 170-179.
14. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007: 17 (2): 93-101.
15. Sistonen J, Madadi P, Ross CJ et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 2012: 91 (4): 692-699.
16. Lotsch J, von Hentig N, Freynhagen R et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009: 19 (6): 429-436.
17. Crews K, Gaedigk A, Dunnenberger H et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012: 91 (2): 321-326.
18. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008: 25 (2): 151-159.
19. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997: 73 (1): 67-74.
20. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005: 352 (22): 2285-2293.
21. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999: 353 (9154): 717-719.
22. Higashi MK, Veenstra DL, Kondo LML et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002: 287 (13): 1690-1698.
23. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008: 111 (8): 4106-4112.
24. Rieder MJ, Reiner AP, Rettie AE. gamma-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007: 5 (11): 2227-2234.
25. Biss TT, Avery PJ, Brandao LR et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012: 119 (3): 868-873.
26. Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol 2012: 34 (4): 984-990.
27. Shaw K, Amstutz U, Hildebrand C et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer 2014. DOI: 10.1002/pbc.2493.
28. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008: 84 (3): 326-331.
29. Klein TE, Altman RB, Eriksson N et al. Estimation of the Warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009: 360 (8): 753-764.
30. The Institute for Pharmacogenomics and Individualized Therapy UoNCM, 2010. iWarfarin. (IPhone application). Version 1.0. Available from Apple Application Store. Retrieved January 2014, from http://ax.itunes.apple.com/us/app/iwarfarin/id359516751?mt=8.
31. Company B-MS. Coumadin® tablets (warfarin sodium tablets, USP) crystalline; Coumadin® for injection (warfarin sodium for injection, USP). Retrived August 9, 2012, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf.
32. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011: 90 (4): 625-629.
33. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012: 141 (Suppl. 2): e152S-e184S.
34. van de Vrie-Hoekstra N, de Vries T, van den Berg P, Brouwer O, de Jong-van den Berg L. Antiepileptic drug utilization in children from 1997-2005 - a study from the Netherlands. Eur J Clin Pharmacol 2008: 64 (10): 1013-1020.
35. Landmark C, Fossmark H, Larsson P, Rytter E, Johannessen S. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011: 95 (1-2): 51-59.
36. Roujeau J, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994: 331 (19): 1272-1285.
37. Genin E, Chen DP, Hung SI et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2013.
38. Chung W-H, Hung S-I, Hong H-S et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004: 428 (6982): 486.
39. Hung S-I, Chung W-H, Jee S-H et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006: 16 (4): 297-306.
40. Amstutz U, Ross CJD, Castro-Pastrana LI et al. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 2013: 94.
41. Ma J, Lee K, Kuo G. Clinical application of pharmacogenomics. J Pharm Pract 2012: 25 (4): 417-427.
42. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006: 6 (4): 265-268.
43. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011: 364 (12): 1134-1143.
44. Chen P, Lin J-J, Lu C-S et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011: 364 (12): 1126-1133.
45. Urban T, Goldstein D. Pharmacogenetics at 50: genomic personalization comes of age. Sci Transl Med 2014: 6 (220).
46. Amstutz U, Shear N, Rieder M et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014.
47. Leckband S, Kelsoe J, Dunnenberger H et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013: 94 (3): 324-328.
48. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995: 13 (4): 228-244.
49. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004: 40 (16): 2445-2451.
50. Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 1990: 61 (6): 927-931.
51. Knight K, Kraemer D, Neuwelt E. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005: 23 (34): 8588-8596.
52. Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011: 12 (7): 1039-1050.
53. Ross CJ, Katzov-Eckert H, Dube MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009: 41 (12): 1345-1349.
54. Caronia D, Patino-Garcia A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009: 9 (5): 347-353.
55. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013: 94 (2): 243-251.
56. Peters U, Preisler-Adams S, Hebeisen A et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000: 11 (8): 639-643.
57. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010: 10 (1): 54-61.
58. Carleton BC, Ross CJ, Bhavsar AP et al. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin Pharmacol Ther 2013: 95: 253.
59. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry. Eur J Cancer 2007: 43 (13): 1967-1975.
60. Canadian Cancer Statistics publication, 2007. http://www.cancer.ca.
61. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002: 13 (6): 819-829.
62. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008: 94 (4): 525-533.
63. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012: 30: 1422-1428.
64. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005: 112 (24): 3754-3762.
65. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009: 23 (6): 1118-1126.
66. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008: 112 (12): 2789-2795.
67. Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children's Oncology Group. J Clin Oncol 2012: 30: 1415-1421.
68. Semsei AF, Erdelyi DJ, Ungvari I et al. ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int 2012: 36: 79-86.
69. Rajic V, Aplenc R, Debeljak M et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009: 50 (10): 1693-1698.
70. Jasminka SG, Tina CI, Aleksandra B, Jasna LK, Gordana J, Sanja K. GSTP1 Ile105Val polymorphism and doxorubicin induced toxicity in children with solid tumors. Robert J. Arceci, ed. 42nd Congress of the International Society of Paediatric Oncology (SIOP); 21-24.10.2010. Boston, USA Pediatric Blood and Cancer/John Wiley & Sons, Inc., 2010.
71. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2011: 118 (7): 1856.
72. Visscher H, Ross CJ, Rassekh SR et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013: 60: 1375-1381.
73. Ramchandren S, Leonard M, Mody R et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 2009: 14 (3): 184-189.
74. Stohr W, Langer T, Kremers A et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005: 23 (3): 201-207.
75. Patrick G. Synonymous mutations break their silence. Nature Rev Genet 2007: 8.
76. Psaty BM, O'Donnell CJ, Gudnason V et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009: 2 (1): 73-80.
77. Carroll D. Precision genome engineering. Curr Biol 2014: 24 (3): R102-R103.
78. Thorrez L, Sampaolesi M. The future of induced pluripotent stem cells for cardiac therapy and drug development. Curr Pharm Des 2011: 17 (30): 3258-3270.
79. Ong FS, Deignan JL, Kuo JZ et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics 2012: 13 (4): 465-475.